Insulin glargine is cost-effective in treatment of patients with diabetes type-2 in whom nph insulin does not provide adequate glycaemic control – The case of poland
Abstract
Authors
D. Szmurlo K. Kostrzewska T. Fundament G. Kopec M. Wojtarowicz R. Drzal G. Stawujak M. Labak-Klimasara M. Glasek J. Lis R. Plisko